{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-029310","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.284578+00:00","generated_at":"2026-06-09T06:07:36.398489+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Reviva announces positive Phase 3 RECOVER trial results for brilaroxazine in schizophrenia","bullets":["Primary endpoint met: brilaroxazine 50 mg showed 10.1-point PANSS reduction vs placebo (p<0.001) at week 4.","Statistically significant improvements in all major symptom domains and secondary endpoints at 50 mg dose.","Well-tolerated with no drug-related SAEs; discontinuation rates lower than placebo (16% vs 22%).","Plans to report OLE topline data in Q4 2024 and initiate Phase 3 RECOVER-2 in Q1 2024; NDA submission expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-029310","json":"https://secwatch.observer/filing/0001437749-23-029310.json","markdown":"https://secwatch.observer/filing/0001437749-23-029310.md","text":"https://secwatch.observer/filing/0001437749-23-029310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923029310/0001437749-23-029310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923029310/rvph20231029_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:07:36.398489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}